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Book Review
Using Cost-Effectiveness Analysis to Improve Health
Care: Opportunities and Barriers by Peter J. Neumann,
Oxford, U.K.: Oxford University Press, 2004. 224 pages;
£19.99; ISBN 0-19-517186-1.
In his recent book, Peter Neumann takes a hard look at
the politics and evolution of cost-effectiveness analysis
(CEA) in the United States. Dr Neumann poignantly
describes the parallel realities that CEA should take on a
more signiﬁcant role in guiding medical practice and
informing health policy and that CEA likely will not
become the basis for medical decision-making. These
opposing truths that CEA can inform rational health-care
practices but is perceived as rationing health-care prac-
tices are the focus of his book. The text describes in con-
siderable detail the perceived value of CEA by various
stakeholders and the reasons that many policy and for-
mulary decision-makers are resistant to fully utilize the
scientiﬁc evidence that CEA brings to evidence-based
medicine.
The broad coverage of topics ranges from efﬁciency
and economic arguments that support CEA to legal and
ethical concerns that limit its political usefulness. Peter
Neumann’s analysis provides fair balance. It does not
provide a one-sided view of the story nor does it suggest
that opponents of CEA are completely misinformed or
misguided. Rather, the chapters explore the source of
resistance to CEA in the United States, providing detailed
descriptions of observations and lessons learned from the
private insurance industry and public payers including
Medicare and the State of Oregon—famous for its exper-
iment with cost effectiveness that went awry.
The book is captivating, often reading more like a
novel than a textbook. The chapters highlight the rela-
tively short history of CEA applied to pharmaceuticals
and other health technologies, describing the barriers as
well as the methodological developments and guidances
that have assisted in its greater acceptance and use. The
author portrays a clear picture of the problems related to
implementing CEA more broadly, because of CEA’s fre-
quently counterintuitive approach to analysis and report-
ing of results. Peter Neumann points out the very real
potential for bias, misreporting, and misinterpretation of
results, especially by medical and policymakers with little
formal statistical training. At the same time, the book
documents the changes that have occurred over time to
support the transparency and interpretability of study
ﬁndings, none of which seem to address the underlying
reality that the United States simply is reluctant to use
economic efﬁciency arguments for deciding which medi-
cines to use. There is a call for more formal education of
health professionals regarding the methods of CEA, but a
realistic view of the potentially limited impact that CEA
training may have on decision-making.
The political support and opposition to CEA are
described, with references to interesting twists and
reversal of positions by key stakeholders including Medi-
care, the Food and Drug Administration (FDA), and pri-
vate insurers. A brief description of the 1997 Food and
Drug Administration Modernization Act (FDAMA) and
the infamous Section 114 provides some glimpses into the
complexity of disseminating CEA information and the
debates over what constitutes “competent and reliable
scientiﬁc evidence.”
There is a logical order to the chapters and appropriate
balance between historical details, results from published
literature, and informed speculation about where the
future of CEA may lie. The cited literature is current and
covers a broad array of contemporary issues with refer-
ences to evidence and opinion from the leading experts in
pharmacoeconomics and health technology assessment.
The uses and potential misuses of CEA are delineated
with reference to potential abuse by both the producers
and users of the information. The book provides both
warnings against biases in reporting by manufacturers
and admonition against using CEA as a smokescreen for
cost containment.
The Academy of Managed Care (AMCP) Format for
Formulary Submission and speciﬁc examples from the
ﬁeld provide evidence of the increasing uptake and impact
of the exponentially increasing CEA literature. Neverthe-
less, the Take-Home Lessons at the conclusion of the
book present a rather dismal outlook for CEA in the fore-
seeable future. “In this climate, there is unlikely to be a
groundswell for CEA . . . Politically, it will probably
remain easier to impose limits by restricting eligibility
rather than services.” Regardless of whether the reader
ﬁnds this conclusion disheartening or well suited, he will
not put the book down without refreshing insight and
new fodder for thought.
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